Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Belite Bio, Inc - American Depositary Shares
(NQ:
BLTE
)
166.28
-12.66 (-7.07%)
Official Closing Price
Updated: 4:15 PM EDT, Aug 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
491,665
Open
178.94
Bid (Size)
163.00 (300)
Ask (Size)
175.00 (200)
Prev. Close
178.94
Today's Range
163.20 - 178.94
52wk Range
60.00 - 200.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Belite Bio Q2 Earnings Call Highlights
↗
Today 18:04 EDT
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the...
Via
MarketBeat
Topics
Earnings
Full Transcript: Belite Bio Q2 2026 Earnings Call
↗
Today 16:53 EDT
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by...
Via
Benzinga
Topics
Earnings
Performance
YTD
+4.4%
+4.4%
1 Month
+13.1%
+13.1%
3 Month
+8.3%
+8.3%
6 Month
-5.0%
-5.0%
1 Year
+128.6%
+128.6%
More News
Read More
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
August 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
August 11, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
August 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases
↗
July 22, 2026
Via
MarketBeat
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
July 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
↗
July 09, 2026
Via
MarketBeat
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Q1 Earnings Call Highlights
↗
May 20, 2026
Via
MarketBeat
Topics
Earnings
Belite Bio (BLTE) Q1 2026 Earnings Transcript
↗
May 20, 2026
Via
The Motley Fool
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
May 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 18, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
May 13, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
April 22, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Frequently Asked Questions
Is Belite Bio, Inc - American Depositary Shares publicly traded?
Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.
What exchange does Belite Bio, Inc - American Depositary Shares trade on?
Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?
The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market
What is the current price of Belite Bio, Inc - American Depositary Shares?
The current price of Belite Bio, Inc - American Depositary Shares is 166.28
When was Belite Bio, Inc - American Depositary Shares last traded?
The last trade of Belite Bio, Inc - American Depositary Shares was at 08/13/26 04:15 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
